Stock MAGLE MAGLE CHEMOSWED HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Magle Chemoswed Holding AB

Equities

MAGLE

SE0014401014

Market Closed - Nasdaq Stockholm
Other stock markets
 11:24:00 2024-05-10 am EDT 		5-day change 1st Jan Change
32 SEK 0.00% Intraday chart for Magle Chemoswed Holding AB 0.00% +26.98%
Apr. 18 Magle Chemoswed Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 22 Magle Chemoswed Holding AB Resolves to Withdraws Dividend Proposal for the Year 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's high margin levels account for strong profits.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • For several months, analysts have been revising their EPS estimates roughly upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
MAGLE CHEMOSWED HOLDING AB Stock Magle Chemoswed Holding AB
+26.98% 31.89M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
B+
NOVARTIS AG Stock Novartis AG
+8.78% 208B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
A+
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. MAGLE Stock
  4. Ratings Magle Chemoswed Holding AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW